Precision Biopsy raises $2.5 million in new funding round - MarketLine Financial Deals

Precision Biopsy raises $2.5 million in new funding round

Precision Biopsy raises $2.5 million in new funding round - MarketLine Financial Deals
Precision Biopsy raises $2.5 million in new funding round
Published Jul 06, 2011
2 pages — Published Jul 06, 2011
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Precision Biopsy, LLC, a US-based developer of optical biopsy technology detect prostate cancer, has raised $2.5 million in new funding led by Allied Minds, Inc.

  
Source:
Document ID
MA70181_110708
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Precision Biopsy raises $2.5 million in new funding round" Jul 06, 2011. Alacra Store. Dec 09, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Precision-Biopsy-raises-2-5-million-in-new-funding-round-2052-63983>
  
APA:
MarketLine Financial Deals. (2011). Precision Biopsy raises $2.5 million in new funding round Jul 06, 2011. New York, NY: Alacra Store. Retrieved Dec 09, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Precision-Biopsy-raises-2-5-million-in-new-funding-round-2052-63983>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.